These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 31051197)

  • 1. Targeting opioid dysregulation in depression for the development of novel therapeutics.
    Browne CA; Lucki I
    Pharmacol Ther; 2019 Sep; 201():51-76. PubMed ID: 31051197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Targets to Treat Depression: Opioid-Based Therapeutics.
    Browne CA; Jacobson ML; Lucki I
    Harv Rev Psychiatry; 2020; 28(1):40-59. PubMed ID: 31913981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine.
    Adzic M; Lukic I; Mitic M; Glavonic E; Dragicevic N; Ivkovic S
    Life Sci; 2023 Aug; 326():121803. PubMed ID: 37245840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094).
    Witkin JM; Wallace TL; Martin WJ
    Handb Exp Pharmacol; 2019; 254():399-415. PubMed ID: 30701317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus.
    D'Oliveira da Silva F; Azevedo Neto J; Sturaro C; Guarino A; Robert C; Gavioli EC; Calo G; Mouledous L; Ruzza C
    Neuropharmacology; 2022 Jul; 212():109077. PubMed ID: 35513173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The opioid system in depression.
    Jelen LA; Stone JM; Young AH; Mehta MA
    Neurosci Biobehav Rev; 2022 Sep; 140():104800. PubMed ID: 35914624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the central opioid system as an antidepressant target in rodent models.
    McHugh KL; Kelly JP
    Prog Brain Res; 2018; 239():49-87. PubMed ID: 30314569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products.
    Hou T; Xu F; Peng X; Zhou H; Zhang X; Qiu M; Wang J; Liu Y; Liang X
    J Ethnopharmacol; 2021 Apr; 270():113872. PubMed ID: 33485984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous opiates and behavior: 2012.
    Bodnar RJ
    Peptides; 2013 Dec; 50():55-95. PubMed ID: 24126281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opiates as antidepressants.
    Berrocoso E; Sánchez-Blázquez P; Garzón J; Mico JA
    Curr Pharm Des; 2009; 15(14):1612-22. PubMed ID: 19442177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
    Olianas MC; Concas D; Onali P
    Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid Mechanisms and the Treatment of Depression.
    Jelen LA; Young AH; Mehta MA
    Curr Top Behav Neurosci; 2024; 66():67-99. PubMed ID: 37923934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders.
    Reed B; Butelman ER; Kreek MJ
    Handb Exp Pharmacol; 2022; 271():473-491. PubMed ID: 33174064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
    Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In major depression, increased kappa and mu opioid receptor levels are associated with immune activation.
    Al-Hakeim HK; Zeki Al-Fadhel S; Al-Dujaili AH; Maes M
    Acta Neuropsychiatr; 2020 Apr; 32(2):99-108. PubMed ID: 31753054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxyl terminal peptides derived from prepro-orphanin FQ/nociceptin (ppOFQ/N) are produced in the hypothalamus and possess analgesic bioactivities.
    Mathis JP; Rossi GC; Pellegrino MJ; Jimenez C; Pasternak GW; Allen RG
    Brain Res; 2001 Mar; 895(1-2):89-94. PubMed ID: 11259764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders.
    Jacobson ML; Browne CA; Lucki I
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():615-636. PubMed ID: 31914893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of opioidergic mechanisms related to the anti-migraine effect of vagus nerve stimulation.
    Hu B; Akerman S; Goadsby PJ
    Neuropharmacology; 2021 Sep; 195():108375. PubMed ID: 33444636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
    Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.